Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

5 recruiting

Enrollment Performance

Analytics

Phase 1
4(66.7%)
Early Phase 1
2(33.3%)
6Total
Phase 1(4)
Early Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT07101705Early Phase 1Recruiting

An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies

Role: collaborator

NCT06891742Phase 1Recruiting

Phase I Study of OriC902 in Treatment of Advanced HCC

Role: collaborator

NCT06271252Phase 1Recruiting

A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study

Role: lead

NCT06182696Phase 1Recruiting

OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM

Role: lead

NCT05652920Phase 1Recruiting

Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC

Role: lead

NCT05016778Early Phase 1Unknown

A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple Myeloma

Role: collaborator

All 6 trials loaded